David Quinn, MD, on impressions of the oral inhibitor study in renal cell carcinoma patients OBRoncology 1:39 4 years ago 135 Скачать Далее
David Quinn, MD, describes if biomarkers help guide treatment in advanced renal cell carcinoma OBRoncology 1:15 4 years ago 21 Скачать Далее
David Quinn, MD, on best utilization of stereotactic radiation in the management of aRCC patients OBRoncology 1:39 4 years ago 21 Скачать Далее
Novel HIF-2a Inhibitor for Patients With Advanced Renal Cell Carcinoma PracticeUpdate 4:13 3 years ago 136 Скачать Далее
David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy OBRoncology 1:53 6 years ago 18 Скачать Далее
David Quinn, MD, on how the measurement of CTC may or may not be changing the treatment of UC OBRoncology 1:01 4 years ago 36 Скачать Далее
Copy of Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC OncLive 1:22 5 years ago 77 Скачать Далее
CAR-T Revolution – Advancing Lymphoma Treatment with Precision & Innovation Emery Pharma 43:17 2 days ago 126 Скачать Далее
Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in OBRoncology 1:42 4 years ago 73 Скачать Далее
Children with cancer to get new gene test The Institute of Cancer Research, London 1:18 8 years ago 658 Скачать Далее
Kynurenine/Tryptophan Is Associated With Biomarkers Of Neurodegenerative Disease Conquer Aging Or Die Trying! 7:57 19 hours ago 2 423 Скачать Далее
Toni Choueiri, MD, provides updates on HIF-2 alpha inhibitors in renal call cancer OBRoncology 3:16 4 years ago 123 Скачать Далее
Eric Jonasch, MD, discusses the incidence of Von Hippel-Lindau Disease among RCC patients OBRoncology 1:00 4 years ago 52 Скачать Далее
Evaluation of Brain Metastases Among Renal Cell Carcinoma Patients Treated With Avelumab & Axitinib PracticeUpdate 4:04 3 years ago 79 Скачать Далее
